Incidence of severe hepatotoxicity related to antiretroviral therapy in HIV/HCV coinfected patients

AIDS Research and Treatment

Volumn 2010, Issue , 2010, Pages

  Heil, Emily L ^a   Townsend, Mary L ^b,c   Shipp, Kenneth ^d   Clarke, Amy ^c   Johnson, Melissa D ^b,d  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b CAMPBELL UNIVERSITY   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054907575     PISSN: 20901240     EISSN: 20901259     Source Type: Journal    
DOI: 10.1155/2010/856542     Document Type: Article

References (10)

1. Sulkowski M. S., Thomas D. L., Hepatitis C in the HIV-infected person. Annals of Internal Medicine 2003 138 3 197 207 2-s2.0-0037418113 (Pubitemid 36231625)
2. Núñez M., Soriano V., Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Safety 2005 28 1 53 66 2-s2.0-12544259261 10.2165/00002018-200528010-00004
3. Sulkowski M. S., Mast E. E., Seeff L. B., Thomas D. L., Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clinical Infectious Diseases 2000 30 supplement 1 S77 S84 2-s2.0-0033799253
4. Sulkowski M. S., Thomas D. L., Chaisson R. E., Moore R. D., Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Journal of the American Medical Association 2000 283 1 74 80 2-s2.0-0034606721 (Pubitemid 30038386)
5. Bonacini M., Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clinical Infectious Diseases 2004 38 supplement 2 S104 S108 2-s2.0-1542297624 10.1086/381453 (Pubitemid 38328172)
6. Lai A. R., Tashima K. T., Taylor L. E., Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus. AIDS Patient Care and STDs 2006 20 10 678 692 2-s2.0-33846440589 10.1089/apc.2006.20. 678 (Pubitemid 46141367)
7. Den Brinker M., Wit F. W. N. M., Wertheim-van Dillen P. M. E., Jurriaans S., Weel J., Van Leeuwen R., Pakker N. G., Reiss P., Danner S. A., Jan Weverling G., Lange J. M. A., Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000 14 18 2895 2902 2-s2.0-0034523342 10.1097/00002030-200012220-00011 (Pubitemid 32042753)
8. Núñez M., Lana R., Mendoza J. L., Martín-Carbonero L., Soriano V., Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2001 27 5 426 431 2-s2.0-0035881188 (Pubitemid 32801070)
9. Sulkowski M. S., Thomas D. L., Mehta S. H., Chaisson R. E., Moore R. D., Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002 35 1 182 189 2-s2.0-0036139688 10.1053/jhep.2002.30319 (Pubitemid 34032559)
10. AIDS Clinical Trials Group, Table of Grading Severity of Adult Adverse Experiences 1996 Rockville, Md, USA Division of AIDS, National Institute of Allergy and Infectious Diseases